In a bid to bolster its oncology pipeline, Ono Pharmaceutical has agreed to acquire multiple research-stage oncology programmes from KSQ Therapeutics. Through the deal, Ono will acquire multiple DNA damage response (DDR) programmes identified using KSQ’s integrated discovery CRISPRomics® platform technology. Interestingly, the deal comes two years after KSQ partnered with Takeda for the development of two T-cell targets.